Clinical Trial Update: An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153) [Phase 3]

View source ↗

Summary

Phase 3 active-controlled extension study updates for Parkinson disease trials have terminated with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Merck Sharp & Dohme LLC

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Parkinson Disease, Idiopathic Parkinson Disease | Phase 3 | Status: TERMINATED | Results posted: 2016-12-12